EQRx is a biotechnology company founded in 2019 and based in Cambridge, Massachusetts, United States. The company's mission is to revamp the drug discovery and delivery process to address the increasing costs of medications. By uniting stakeholders across the healthcare sector and harnessing the latest scientific and technological advancements, EQRx aims to efficiently develop and distribute high-quality, patent-protected medicines.
With a focus on collaborative healthcare innovation, EQRx seeks to provide market-driven solutions to the pharmaceutical industry's cost challenges. The company's recent milestone includes a significant $1.20B Post-IPO Equity investment at 17 December 2021, with contributions from notable investors such as Andreessen Horowitz/a16z, Franklin Templeton Venture Capital, Boxer Capital, Invus, Mubadala, Bain Capital Life Sciences, Corvex, Mubadala Capital Ventures, Biotechnology Value Fund, and SB Life Science.
EQRx's approach towards reshaping the pharmaceutical landscape and its notable backing from prominent investors positions it as a key player in the biotechnology, healthcare, and pharmaceutical industries.
